NeuroSense Therapeutics Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 3.89 million compared to USD 2.72 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.24 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.165 USD | +1.30% | -10.85% | +46.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.50% | 19.93M | |
+4.03% | 111B | |
+11.43% | 105B | |
-12.67% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+2.37% | 13.7B | |
+36.28% | 12.45B |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023